Advertisement
CLLS vs MDGL
Which Stock Would AI Choose? Cellectis S.A. (CLLS) vs. Madrigal Pharmaceuticals, Inc. (MDGL) Stock Comparison
Key Takeaways
- CLLS, a clinical-stage gene-editing biotech, has shown strong one-year gains of approximately 197%, driven by recent market momentum, but remains pre-revenue with higher volatility.
- MDGL, focused on MASH treatments, boasts a marketed product Rezdiffra with $958 million in 2025 sales, supporting a $12 billion market cap and steadier recent performance.
- Recent weeks have seen CLLS up over 24% monthly amid biotech sector interest, while MDGL gained about 19%, reflecting commercial traction.
- MDGL offers revenue stability and pipeline expansion, contrasting CLLS's higher-risk, high-reward clinical pipeline in immuno-oncology.
- Year-to-date, CLLS edges positive returns around 11%, versus MDGL's slight decline, highlighting divergent risk profiles.
- Both stocks exemplify biotech contrasts: speculative gene-editing versus commercialized metabolic therapies.
Introduction
This comparison examines CLLS and MDGL, two biotechs navigating distinct paths in gene editing and metabolic liver disease treatments. Traders seeking momentum plays may eye CLLS's volatility, while long-term investors might favor MDGL's revenue generation. In the current market, with biotech sentiment buoyed by clinical data and commercial launches, this analysis highlights relative performance, sector exposure, and positioning to aid informed stock comparison decisions.
CLLS Overview and Recent Performance
Cellectis S.A. (CLLS) is a clinical-stage biotechnology company headquartered in Paris, specializing in gene-editing technologies for allogeneic chimeric antigen receptor T-cell (CAR-T) therapies in immuno-oncology and other indications. Its pipeline includes candidates like BALLI-01 for relapsed/refractory acute lymphoblastic leukemia (ALL) and NatHaLi-01 for B-cell non-Hodgkin's lymphoma (B-NHL).
Recent market activity has propelled CLLS shares higher, with approximately 24% gains over the past month and over 27% in the last five days, trading around $4.28 amid elevated volume near 46,000 shares daily. Year-to-date returns stand positive at about 11%, building on a remarkable 197% one-year surge from lows near $1.33 to highs of $5.48. Sentiment has been influenced by ongoing clinical advancements and broader biotech momentum, though the company reports net losses and remains pre-revenue, with a market cap around $440 million. Volatility persists, reflected in a beta over 2.7, as investors weigh pipeline progress against funding needs.
MDGL Overview and Recent Performance
Madrigal Pharmaceuticals, Inc. (MDGL) is a biopharmaceutical firm targeting metabolic dysfunction-associated steatohepatitis (MASH), formerly NASH, with its lead product Rezdiffra (resmetirom), the first FDA-approved therapy for non-cirrhotic MASH with moderate to advanced fibrosis.
In recent market activity, MDGL shares have risen about 19% over the past month, trading near $525 with average daily volume around 370,000 shares. The stock delivered 66% one-year returns, ranging from $265 to $615, though year-to-date it's slightly down amid sector pressures. Rezdiffra drove blockbuster-level 2025 net sales of $958 million, up significantly from prior periods, fueling a $12 billion market cap. Positive sentiment stems from strong adoption, pipeline expansions like siRNA licensing, and robust revenue growth, offsetting ongoing losses while providing commercial validation in a high-unmet-need area.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases 25 top-performing AI trading bots curated from 351 total bots, engineered to outperform across growth sectors with real-time signals for copy trading in stocks, ETFs, and crypto. These bots employ diverse strategies like AI/ML, technical analysis, and multi-agent approaches on timeframes from 5min to 60min, trading sets of tickers from 3 to 25 across industries. Top performers boast annualized returns up to +137%, win rates to 87%, and profit factors exceeding 6, with equity growth examples like $48,783 on $100,000 balances. Only the most suitable for current conditions earn a spot here, highlighting varying styles, performances, and risk controls. Explore Tickeron’s AI trading bots to leverage these insights in your strategy.
Head-to-Head Comparison
CLLS and MDGL operate in biotech but diverge sharply: CLLS pursues high-risk gene-editing for oncology CAR-Ts (off-the-shelf allogeneic therapies), while MDGL targets MASH with a commercialized oral THR-β agonist. Growth drivers contrast—CLLS relies on clinical milestones amid net losses of $37 million annually, versus MDGL’s $958 million Rezdiffra sales enabling pipeline bolstering.
Recent momentum favors CLLS (24% monthly vs. 19%), but MDGL shows stability with higher liquidity. Risk factors include CLLS’s trial delays and dilution potential (beta 2.7), against MDGL’s competition in MASH. Sector exposure pits immuno-oncology volatility against metabolic disease commercialization, with market sentiment leaning toward revenue-proven plays amid biotech funding tightness.
Tickeron AI Verdict
Tickeron’s AI currently favors MDGL due to its trend consistency via Rezdiffra sales growth, commercial stability, and expanding catalysts like licensing deals, positioning it strongly relative to CLLS’s speculative clinical momentum. While CLLS offers upside from pipeline successes, MDGL’s revenue base suggests higher probability of sustained outperformance in the near term.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CLLS is a Hold and MDGL is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CLLS’s FA Score shows that 0 FA rating(s) are green whileMDGL’s FA Score has 1 green FA rating(s).
- CLLS’s FA Score: 0 green, 5 red.
- MDGL’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CLLS’s TA Score shows that 4 TA indicator(s) are bullish while MDGL’s TA Score has 2 bullish TA indicator(s).
- CLLS’s TA Score: 4 bullish, 7 bearish.
- MDGL’s TA Score: 2 bullish, 6 bearish.
Price Growth
CLLS (@Biotechnology) experienced а -2.53% price change this week, while MDGL (@Biotechnology) price change was -4.17% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +5.02%. For the same industry, the average monthly price growth was +7.74%, and the average quarterly price growth was +9.80%.
Reported Earning Dates
CLLS is expected to report earnings on May 11, 2026.
MDGL is expected to report earnings on Aug 11, 2026.
Industries' Descriptions
@Biotechnology (+5.02% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| CLLS | MDGL | CLLS / MDGL | |
| Capitalization | 379M | 11.5B | 3% |
| EBITDA | -6.07M | -281.09M | 2% |
| Gain YTD | -20.455 | -14.650 | 140% |
| P/E Ratio | N/A | N/A | - |
| Revenue | 75.3M | 1.13B | 7% |
| Total Cash | 190M | 813M | 23% |
| Total Debt | 92.8M | 347M | 27% |
CLLS | MDGL | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 36 Fair valued | 65 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 23 | |
SMR RATING 1..100 | 96 | 98 | |
PRICE GROWTH RATING 1..100 | 40 | 47 | |
P/E GROWTH RATING 1..100 | 100 | 100 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
CLLS's Valuation (36) in the Biotechnology industry is in the same range as MDGL (65) in the Pharmaceuticals Other industry. This means that CLLS’s stock grew similarly to MDGL’s over the last 12 months.
MDGL's Profit vs Risk Rating (23) in the Pharmaceuticals Other industry is significantly better than the same rating for CLLS (100) in the Biotechnology industry. This means that MDGL’s stock grew significantly faster than CLLS’s over the last 12 months.
CLLS's SMR Rating (96) in the Biotechnology industry is in the same range as MDGL (98) in the Pharmaceuticals Other industry. This means that CLLS’s stock grew similarly to MDGL’s over the last 12 months.
CLLS's Price Growth Rating (40) in the Biotechnology industry is in the same range as MDGL (47) in the Pharmaceuticals Other industry. This means that CLLS’s stock grew similarly to MDGL’s over the last 12 months.
CLLS's P/E Growth Rating (100) in the Biotechnology industry is in the same range as MDGL (100) in the Pharmaceuticals Other industry. This means that CLLS’s stock grew similarly to MDGL’s over the last 12 months.
| CLLS | MDGL | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 85% | 5 days ago 90% |
| Stochastic ODDS (%) | 4 days ago 82% | 5 days ago 87% |
| Momentum ODDS (%) | 4 days ago 90% | 4 days ago 85% |
| MACD ODDS (%) | 4 days ago 90% | 4 days ago 88% |
| TrendWeek ODDS (%) | 4 days ago 86% | 4 days ago 83% |
| TrendMonth ODDS (%) | 4 days ago 71% | 4 days ago 81% |
| Advances ODDS (%) | 6 days ago 78% | 20 days ago 77% |
| Declines ODDS (%) | 4 days ago 88% | 4 days ago 81% |
| BollingerBands ODDS (%) | 4 days ago 85% | 4 days ago 87% |
| Aroon ODDS (%) | 4 days ago 87% | 5 days ago 61% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| GCINX | 15.94 | 0.16 | +1.01% |
| Green Century MSCI Intl Indx Indvl Inv | |||
| INDCX | 14.65 | 0.06 | +0.41% |
| Victory Pioneer Disciplined Growth C | |||
| PMDIX | 21.94 | 0.08 | +0.37% |
| Principal Small-MidCap Dividend Inc Inst | |||
| FSRKX | 9.63 | 0.03 | +0.31% |
| Fidelity Strategic Real Return K6 | |||
| TWHIX | 20.85 | -0.24 | -1.14% |
| American Century Heritage Inv | |||